Obesity Impairs Skeletal Muscle Regeneration Through Inhibition of AMPK

Xing Fu1, Meijun Zhu2, Shuming Zhang2

  • 1Washington Center for Muscle Biology, Department of Animal Sciences and Department of Pharmaceutical Sciences, Washington State University, Pullman, WA.

Diabetes
|September 19, 2015
PubMed

Insights

Obesity impairs muscle regeneration by inhibiting AMPK activity, particularly AMPKα1 in satellite cells. Restoring AMPK activity with AICAR can rescue this impairment, highlighting AMPKα1 as a therapeutic target for obesity-related muscle issues.

Area of Science:

  • Muscle biology
  • Metabolic disorders
  • Cellular signaling

Background:

  • Obesity is a global health crisis linked to numerous complications, including compromised muscle repair.
  • Reduced AMP-activated protein kinase (AMPK) activity is a hallmark of obesity across various tissues.
  • The precise mechanisms by which obesity-induced AMPK inhibition affects muscle regeneration remain unclear.

Purpose of the Study:

  • To investigate the role of AMPK activity in obesity-associated muscle regeneration deficits.
  • To determine if AMPKα1 is a critical mediator in this process.
  • To evaluate AICAR as a potential therapeutic agent for improving muscle regeneration in obese individuals.

Main Methods:

  • Comparative analysis of muscle regeneration in obese and lean mice.
  • Genetic manipulation to specifically knock out AMPKα1 in satellite cells.
  • Assessment of satellite cell activation, proliferation, and differentiation post-injury.
  • Functional evaluation of muscle regeneration following AICAR treatment in different genetic contexts.

Main Results:

  • Obesity was confirmed to inhibit AMPK activity in regenerating muscle, correlating with impaired satellite cell function and regeneration.
  • Satellite cell-specific AMPKα1 knockout mimicked the regenerative deficits observed in obesity, reducing satellite cell proliferation and differentiation.
  • AICAR treatment successfully rescued muscle regeneration in obese mice but not in those with satellite cell-specific AMPKα1 knockout.
  • Transplantation of AMPKα1-deficient satellite cells demonstrated severely impaired myogenic capacity.

Conclusions:

  • AMPKα1 is a crucial mediator linking obesity to impaired muscle regeneration.
  • Targeting AMPKα1 within satellite cells offers a promising therapeutic strategy for enhancing muscle repair in obese populations.
  • AMPK activation represents a viable approach to counteract obesity-induced muscle regeneration defects.

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
9.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
284
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
384
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.7K